We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Economic Analysis: Randomized Placebo-Controlled Clinical Trial of Erlotinib in Advanced Non–Small Cell Lung Cancer.
- Authors
Bradbury, Penelope A.; Tu, Dongsheng; Seymour, Lesley; Isogai, Pierre K.; Zhu, Liting; Ng, Raymond; Mittmann, Nicole; Tsao, Ming-Sound; Evans, William K.; Shepherd, Frances A.; Leighl, Natasha B.
- Abstract
Background: The NCIC Clinical Trials Group conducted the BR.21 trial, a randomized placebo-controlled trial of erlotinib (an epidermal growth factor receptor tyrosine kinase inhibitor) in patients with previously treated advanced non–small cell lung cancer. This trial accrued patients between August 14, 2001, and January 31, 2003, and found that overall survival and quality of life were improved in the erlotinib arm than in the placebo arm. However, funding restrictions limit access to erlotinib in many countries. We undertook an economic analysis of erlotinib treatment in this trial and explored different molecular and clinical predictors of outcome to determine the cost-effectiveness of treating various populations with erlotinib.
- Subjects
RANDOMIZED controlled trials; CLINICAL trials; EPIDERMAL growth factor; PROTEIN-tyrosine kinases; PLACEBOS
- Publication
JNCI: Journal of the National Cancer Institute, 2010, Vol 102, Issue 5, p298
- ISSN
0027-8874
- Publication type
Article
- DOI
10.1093/jnci/djp518